SCM
MRNA icon

Suvretta Capital Management’s Moderna MRNA Stock Holding History

Suvretta Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-111,400
Closed -$7.88M – 118
2020
Q3 		$7.88M Buy
+111,400
New +$7.77M 0.14% 58

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Suvretta Capital Management's MRNA Position: Q1 2026 in Review

Suvretta Capital Management sold out of Moderna (MRNA) in Q1 2026, closing a stake of 205,593 shares — an estimated $6.06M sold.

Suvretta Capital Management first reported a position in MRNA in Q1 2025 and held it in 3 quarters. The position peaked at $14.7M in Q1 2025. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Suvretta Capital Management reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
  • Suvretta Capital Management sold 205,593 Moderna shares in Q1 2026, an estimated $6.06M.
  • Suvretta Capital Management first reported a position in Moderna in Q1 2025 and held it in 3 quarters.
  • Suvretta Capital Management's Moderna position peaked at $14.7M in Q1 2025.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Suvretta Capital Management's 13F filing for Q1 2026, filed 15 May 2026.